Attovia Therapeutics Launches with $60 Million Series A Financing to Unlock Potential of Novel Biparatopic Nanobody Platform
Company Formed by Alamar Biosciences and Frazier Life Sciences Attobody™ Platform Generates Small Format Binders for Hard-to-drug Targets FREMONT and MENLO PARK– June 20, 2023 – Alamar Biosciences, a company […]
Alamar Biosciences Unveils Novel Proteomics Platform with Best-in-Class Sensitivity and High Multiplexing Capability
Alamar Biosciences Unveils Novel Proteomics Platform with Best-in-Class Sensitivity and High Multiplexing Capability Multiplex analysis of 204 serum proteins with attomolar sensitivity and 10 logs dynamic range enables accurate measurement […]
Mologic and Alamar Biosciences collaborate to develop a next generation COVID-19 antigen test
• Mologic leverages Alamar’s ultra-high affinity antibodies for SARS-CoV-2 diagnostics • Partnership will facilitate rapid responses to future pandemics Bedfordshire, UK and Fremont, CA, US – 4 May 2022 – […]
SciNeuro Pharmaceuticals and Alamar Biosciences Collaborate to Discover Novel Therapeutic Antibodies for CNS Diseases
Fremont, CA and Rockville, MD – 15 February 2022 – Alamar Biosciences (Alamar), a platform company focused on transforming the field of proteomics to enable the early detection of cancer […]
Alamar Biosciences partners with Abcam to drive understanding of the human proteome
Alamar selects Abcam as a key provider of antibody content for its proprietary NULISA technology platform Fremont, CA, US and Cambridge, UK – 04 January 2022 – Alamar Biosciences (Alamar), […]
Alamar Biosciences Completes $80M Series B Fundraising to Bring Unprecedented Performance to the Proteomics Market
Fremont, CA, September 8, 2021 (PR NEWSWIRE) — Alamar Biosciences, Inc., a precision proteomics company that brings both ultra-high sensitivity and massively parallel scale to proteomic analysis, announced today that […]